Miriplatin

Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).[1][2] Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.[1]

Miriplatin
Clinical data
Trade namesMiripla
Legal status
Legal status
  • Rx in Japan
Identifiers
IUPAC name
  • Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC34H68N2O4Pt
Molar mass764.012 g·mol−1
3D model (JSmol)
SMILES
  • CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CC[C@]([H])([C@@]([H])(C1)N)N.[Pt+2]
InChI
  • InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1
  • Key:BGIHRZPJIYJKAZ-BLUNCNMSSA-L

See also

References
  1. "Miriplatin". Inxight Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
  2. Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, et al. (February 2018). "Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial". Journal of Gastroenterology. 53 (2): 281–290. doi:10.1007/s00535-017-1374-6. PMC 5846877. PMID 28766016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.